17
Views
7
CrossRef citations to date
0
Altmetric
Review

Prion diseases: update on therapeutic patents (1999 – 2002)

&
Pages 67-78 | Published online: 02 Mar 2005

Bibliography

  • COLLINGE J: Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neuroscl (2001) 24:519–550.
  • PRUSINER SB: Shattuck lecture - neurodegenerative diseases and prions. N Engl. J. Med. (2001) 344:1516–1526.
  • AL-SHAHI R, WILL RG, WARLOW CP: Amount of research interest in rare and common neurological conditions: bibliometric study. Br. Med." (2001) 323:1461–1462.
  • PROUT KA, LARNER AJ: Emerging therapeutic possibilities in prion diseases: patents 1993-1998. Exp. Opin. The]: Patents (1998) 8(9):1099–1108.
  • KNIGHT R: Therapeutic possibilities in CJD: patents 1996-1999. Exp. Opin. Thec Patents (2000) 10(1):49–57.
  • COLLINGE J, PALMER MS (Eds): Prion diseases. OUP, Oxford (1997).
  • PRUSINER SB (Ed.): Prion biology and diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1999).
  • BROWN P: Transmissible spongiform encephalopathies. In: Early-onset dementia: a multidisciplinary approach. Hodges JR (Ed.), OUP, Oxford, UK (2001):367–384.
  • PARCHI P, GAMBETTI P: Prion diseases and dementia. In: Molecular mechanisms of dementia. Wasco W, Tanzi RE (Eds), Humana, Totowa NJ, USA (1997):293–306.
  • SY MS, GAMBETTI P, WONG BS: Human prion diseases. Med. Gin. North Am. (2002) 86:551–571.
  • SCARAVILLI F, CORDERY RJ, KRETSCHMAR H et al.: Sporadic fatal insomnia: a case study. Ann. Neural (2000) 48:665–668.
  • KOVACS GG, TRABATTONI G, HAINFELLNER JA, IRONSIDE JW, KNIGHT RSG, BUDKA H: Mutations of the prion protein gene: phenotypic spectrum. J. Neurol (2002) 249:1567–1582.
  • GAJDUSEK DC: Unconventional viruses and the origin and disappearance of kuru. Science (1977) 197:943–960.
  • ZIGAS V: Laughing death: the untold story of kuru. Humana, Clifton NJ (1990).
  • COLLINGE J: Variant Creutzfeldt-Jakob disease. Lancet (1999) 354:317–323.
  • SPENCER MS, KNIGHT RSG, WILL RG: First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. Br. Med. J. (2002) 324:1479–1482.
  • MANNS D, BOUMAN W: CJD presenting with psychotic symptoms. Progress M Neurology and Psychiatry (2000) 4(6):29.
  • PALMER MS, DRYDEN AJ, HUGHES JT, COLLINGE J: Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature (1991) 352:340–342.
  • FOX NC, FREEBOROUGH PA, MEKKAOUI KF, STEVENS JM, ROSSOR MN: Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease. Br. Med. .1. (1997) 315:856–857.
  • ZEIDLER M, SELLAR RJ, COLLIE DA et al: The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet (2000) 355:1412–1418.
  • COLLIE DA, SELLARRJ, ZEIDLER M,COLCHESTER ACE KNIGHT R, WILL RG: MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. an. Radial. (2001) 56:726–739.
  • DA SILVA R, PATTERSON J, HADLEY D, RUSSELL A, TURNER M, ZEIDLER M: Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports. Br. Med. J. (1998) 316:593–594.
  • ZERR I, POCCHIARI M, COLLINS S et al: Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 55:811–815.
  • TSCHAMPA HJ, NEUMANN M, ZERR I et al: Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J. Nemo]. Neurosurg. Psychiatry (2001) 71:33–39.
  • IRONSIDE J, LOWMAN A: The diagnosis of variant Creutzfeldt-Jakob disease. Adv. Gin. Neurosci. Rehabilitation (2002) 1(6):6–8.
  • COLLINGE J, OWEN F, POULTER M et al.: Prion dementia without characteristic pathology. Lancet (1990) 336:7–9.
  • HILTON DA, FATHERS E, EDWARDS P, IRONSIDE JW, ZAJICEK J: Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet (1998) 352:703–704.
  • HILTON D, GHANI AC, CONYERS L et al.: Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br. Med. J. (2002) 325:633–634.
  • HILL AF, BUTTERWORTH RJ, JOINERS et al.: Investigation of variant Creutzfeldt-Jakob disease and other human prion disease with tonsil biopsy samples. Lancet (1999) 353:183–189.
  • HEGDE RS, TREMBLAY P, GROTH D, DEARMOND SJ, PRUSINER SB, LINGAPPA VR: Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature (1999) 402:822–826.
  • COLLINGE J, WHITTINGTON MA, SIDLE KCL et at Prion protein is necessary for normal synaptic function. Nature (1994) 370:295–297.
  • BROWN DR, WONG B-S, HAFIZ F, CLIVE C, HAS WELL SJ, JONES IM: Normal prion protein has an acitivity like that of superoxide dismutase. Biochem. (1999) 344:1–5.
  • KUWAHARA C, TAKEUCHI AM, NISHIMURA T et at Prions prevent neuronal cell-line death. Nature (1999) 400:225–226.
  • BROWN DR, QIN K, HEWS JW et at The cellular prion protein binds copper in vivo. Nature (1997) 390:684–687.
  • PAN K-M, BALDWIN M, NGUYEN J et at Conversion of a-helices into I3-sheets features in the formation of the scarpie prion proteins. Proc. Nati Acad. Sci. USA (1993) 90:10962–10966.
  • TELLING GC, SCOTT M, MASTRIANNI J et al.: Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell (1995) 83:79–90.
  • TELLING GC, PARCHI P, DEARMOND SJ et al.: Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science (1996) 274:2079–2082.
  • SAFAR J, WILLE H, ITRI Vet al.: Eight prion strains have PrPSc molecules with different conformations. Nature Med. (1998) 4:1157–1165.
  • KLEIN MA, FRIGG R, FLECHSIG E et at A crucial role for B cells in neuroinvasive scrapie. Nature (1997) 390:687–690.
  • •The first demonstration that B lymphocytes play a role in disease pathogenesis after peripheral inoculation of prions.
  • KLEIN M, FRIGG R, RAEBER A et at PrP expression in B-lymphocytes is not required for prion neuroinvasion. Nature Med. (1998) 4:1429–1433.
  • LASMEZAS CI, DESLYS J-P, ROBAIN O et al.: Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science (1997) 275:402–405.
  • FORLONI G, TAGLIAVINI F, BUGIANI O, SALMONA M: Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Prog. Neurobiol (1996) 49:287–315.
  • KUNZ B, SANDMEIER E, CHRISTEN P: Neurotoxocity of prion peptide 106-126 not confirmed. FEBS Lett. (1999) 458:65–68.
  • LARNER AJ, SOFRONIEW MV: Mechanisms of cellular damage and recovery. In: Handbook of neurological rehabilitation (2nd edition). Greenwood R, Barnes MP, McMillan TM, Ward CD (Eds), Psychology Press, London (2002):71–98.
  • MILHAVET O, LEHMANN S: Oxidative stess and the prion protein in transmissible spongiform encephalopathies. Brain Res. Brain Res. Rev. (2002) 38:328–339.
  • LEBLANC A: Unraveling the controversy of human prion protein diseases. In: Handbook of the Aging Brain. Wang E, Snyder DS (Eds), Academic, San Diego (1998):201–221.
  • DORANDEAU A, WINGERTSMANN L, CHRE.TIEN F et at Neuronal apoptosis in fatal familial insomnia. Brain Pathol. (1998) 8:531–537.
  • GRAY F, CHRE.TIEN F, ADLE-BIASSETTE H et al: Neuronal apoptosis in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. (1999) 58:321–328.
  • BROWN DR, SCHMIDT B, KRETZSCHMAR HA: Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature (1996) 380:345–347.
  • HEPPNER FL, PRINZ M, AGUZZI A: Pathogenesis of prion diseases: possible implications of microglial cells. Prog. Brain Res. (2001) 132:737–750.
  • REZAIE P, LANTOS PL: Microglia and the pathogenesis of spongiform encephalopathies. Brain Res. Brain Res. Rev. (2001) 35:55–72.
  • FARQUHAR C, DICKINSON A, BRUCE M: Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet (1999) 353:117.
  • DEALLER S: Post-exposure prophylaxis after accidental prion inoculation. Lancet (1998) 351:600.
  • WONG C, XIONG LW, HORIUCHI M et al.: Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO (2001) 20:377–386.
  • SUPATTAPONE S, NGUYEN HOB, COHEN FE, PRUSINER SB, SCOTT MR: Elimination of prions by branched polyamines and implications for therapeutics. Proc. Nati Acad. Sci. USA (1999) 96:14529–14534.
  • PERETZ D, WILLIAMSON RA, KANEKO K et al.: Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 412:739–743.
  • •Demonstration that specific antiprion antibodies can block prion propagation within cells.
  • HEPPNER FL, MUSAHL C, ARRIGHI I et at Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 294:178–182.
  • •Demonstration that specific antiprion antibodies can block prion propagation within cells.
  • SOLOMON B, KOPPEL R, HANAN E, KATZAV T: Monoclonal antibodies inhibit M vitro fibrillar aggregation of the Alzheimer 13-amyloid peptide. Proc. Natl. Acad. Sci. USA (1996) 93:452–455.
  • BARD F, CANNON C, BARBOUR R et at Peripherally administered antibodies against amyloid 13-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. (2000) 6:916–919.
  • SOTO C, KASCSAK RJ, SABORIO GP et al.: Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides. Lancet (2000) 355:192–197.
  • SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-I3 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
  • WEINER HL, LEMERE CA, MARON R et al.: Nasal administration of amyloid-I3 peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. (2000) 48:567–579.
  • JANUS C, PEARSON J, MCLAURIN J et al.: A13 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
  • MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: A13 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982–985.
  • SIGURDSSON EM, BROWN DR, DANIELS M et al.: Immunization delays the onset of prion disease in mice. Am. J. Pathol. (2002) 161:13–17.
  • •Use of PrP peptides as a vaccine to delay the onset of prion disease by induction of anti-PrP antibodies.
  • KORTH C, MAY BC, COHEN FC, PRUSINER SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Nati Acad. ScL USA (2001) 98:9836–9841.
  • ••Demonstration that quinacrine andchlorpromazine, amongst others, can inhibit prion propagation in cell cultures. Since these two drugs are already in clinical use for other indications, with well characterised side effect profiles, clinical trials in prion disease have commenced.
  • AGUZZI A, COLLINGE J: Post-exposure prophylaxis after accidental prion inoculation. Lancet (1997) 350:1519–1520.
  • KORTH C, STIERLI B, STREIT P et al: Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature (1997) 390:74–77.
  • CAUGHEY B: Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nature Med. (2000) 6:751–754.
  • PRIOLA S, RAINES A, CAUGHEY WS: Porphyrin and phthalocyanine antiscrapie compounds. Science (2000) 287:1503–1506.
  • CAUGHEY B: Interactions between prion protein isoforms: the kiss of death? Trends Biochem. Sci. (2001) 26:235–242.
  • MANTHORPE M, FAGNANI R, SKAPER SD, VARON S: An automated colorimetric microassay for neuronotrophic factors. Dev. Brain Res. (1986) 25:191–198.
  • SMITH MA, ATWOOD CS, JOSEPH JA, PERRY G: Predicting the failure of amyloid-I3 vaccine. Lancet (2002) 359: 1864-1865.
  • ASHWELL S: Caspases: recent advances in small molecule inhibitors. Exp. Opin. Then Patents (2001) 11 (10) :1593–1603.
  • LARNER AJ: Poly(ADP-ribose) polymerase inhibitors in the prevention of neuronal cell death. Exp. Opin. Then Patents (2002) 12(4):481–487.
  • OTTO M, BOEKHOFF I, RATZKA P et al: First therapeutic experience with flupirtine in patients with Creutzfeldt-Jakob disease. J. Neurol. (1998) 245:486 (abstract P549).
  • LARNER AJ: Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Exp. Opin. Then Patents (2000) 10(10):1493–1518.
  • SZALLASI A, FOWLER CJ: After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurology (2002) 1:167–172.
  • MUQIT MMK, FEANY MB: Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev Neurosci. (2002) 3:237-243. ao. TARNOPOLSKY MA, BEAL MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. (2001) 49:561–574.
  • SCHNEIDER C, BECK M, GEORGE A et al.: Creatine monohydrate in proximal myotonic myopathy (PROMM): a double-blind, placebo-controlled clinical study. Neurology (2002) 58 (supp13):A225 (abstract P03.126).
  • QIZILBASH N: Evidence-based interventions. In: Evidence-based dementia practice. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (Eds), Blackwell, Oxford (2002):31–41.
  • LARNER Al: Alzheimer's disease: targets for drug development. Mini-reviews in Medicinal Chemistry (2002) 2(1): 1–9.
  • CONDE S: P-Amyloid peptide as a target for treatment of Alzheimer's disease. Exp. Opin. Ther. Patents (2002) 12 (4):503–512.
  • EMRE M: Drugs in development and experimental approaches. In: Evidence-based dementia practice. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (Eds), Blackwell, Oxford (2002):447–457.
  • COLLINS SJ, LEWIS V, BRAZIER M, HILL AF, FLETCHER A, MASTERS CL: Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. (2002) 52:503–506.
  • MULLER WE, LAPLANCHE JL, USHIJIMA H, SCHRODER HC: Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech. Ageing Dev. (2001) 116:193–218.
  • OTTO M, RATZKA P, DOEHLINGER S et al.: Efficacy of flupirtine on cognitive function in patients with Creutzfeldt-Jakob disease. Neurobiol. Aging (2002) 23(1S):5131-5132 (abstract 497).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.